In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
Mutual fund industry veteran Frank Nasta, who retired from JPMorgan's U.S. funds business in mid-2018, is among three new independents nominated to join the Federated Hermes ...
Building and maintaining a diverse membership has become a top priority for many mutual fund boards in recent years, and new data shows this focus is ...
Total compensation paid to independent mutual fund directors in 2023 increased, though the difference was smaller than in the year prior, according to industry data obtained ...
The Putnam Funds board has new leadership and a new independent member following the retirement of Kenneth Leibler, who chaired the board for six years and ...